You just read:

Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment Methods for Generic Peptide Drugs and Their Impurities

News provided by

EpiVax, Inc.

02 Oct, 2018, 06:00 BST